Latest news with #AssociationforResearchinVisionandOphthalmology
Business Upturn
2 days ago
- Business
- Business Upturn
HOYA Vision Care Unveils Updates from the Association for Research in Vision and Ophthalmology (ARVO) 2025 Annual Meeting
Salt Lake City, United States: Latest evidence from the world's longest running study on myopia management spectacle lenses reinforced the effectiveness of Defocus Incorporated Multiple Segments (D.I.M.S.) Technology in continuing to significantly reduce myopia progression and axial elongation over 8 years 1 Findings from the randomized controlled trial, ASPECT, demonstrated that combining 0.025% atropine drops with DIMS spectacle lenses reduces axial elongation in myopic children 2 A first-of-its-kind concept trial showed that D.I.M.S. Technology may offer a protective effect against the development of myopia in pre-myopic preschool children and postpone the onset of myopia3 HOYA Vision Care ( today announced new clinical evidence from three key clinical studies highlighting the impact of Defocus Incorporated Multiple Segments (D.I.M.S.) Technology. The results were presented as part of the company's 2025 scientific program, Exploring New Frontiers in Myopia Management with MiYOSMART*, at the Association for Research in Vision and Ophthalmology (ARVO) 2025 Annual Meeting in Salt Lake City, Utah, USA. The latest findings from the world's longest-running clinical study on myopia management spectacle lenses showed that continuous DIMS spectacle lens wear demonstrated significantly reduced myopia progression (-1.00D ± 0.41D, p=0.017) and axial elongation (0.42 ± 0.18 mm, p=0.019) consistently for the full 8 years (n=11) of follow-up.1 This evidence demonstrates that wearing MiYOSMART* spectacle lenses continuously and for the long-term may improve myopia management outcomes. Dr. Natalia Vlasak, Global Head of Medical and Scientific Affairs at HOYA Vision Care said 'This landmark study, featuring the longest follow-up to date for myopia management spectacle lenses, reveals that long-term MiYOSMART use continues to significantly slow myopia progression so that children can enjoy their lives to the fullest. These findings emphasize the life-changing value of long-term adherence, providing crucial information and guidance for Eye Care Professionals and parents committed to protecting children's vision health for the future.' The first 12-month data readout from the ASPECT randomized controlled trial demonstrated that combining low-dose 0.025% atropine eye drops with DIMS spectacle lenses stopped myopia progression in around 40% of children.2 The mean change in axial length, a key factor in myopia progression, was significantly lower than in the atropine-only group (0.07 ± 0.16 mm vs 0.18 ± 0.16 mm; p<0.001). The researchers also explored vision-related quality of life (VR-QoL), indicating a trend towards improvement in general vision (p=0.049) and competence (p=0.031) in children using low-dose atropine and DIMS spectacle lens combination treatment.4 'Our findings suggest that combining MiYOSMART spectacle lenses with atropine can unlock even greater outcomes for children with myopia progression – marking a positive step towards more personalized, powerful treatment strategies in myopia management that suit the unique needs of each child.' said Dr Natalia Vlasak, Global Head of Medical and Scientific Affairs at HOYA Vision Care. A first-of-its-kind pilot study evaluating DIMS spectacle lenses for pre-myopia management in 5- and 6-year-old children indicated that the DIMS technology may offer a protective effect against the development of myopia in this population. Over nine months, the average cycloplegic spherical equivalent refraction (SER) remained stable with a yearly change of +0.06D compared to -0.15D in a control group. While axial length increased slightly (22.48 mm to 22.64 mm, p<0.01), the choroidal thickness remained stable. These promising initial findings suggest MiYOSMART spectacle lenses may help to prevent myopia development and postpone the myopia onset in pre-myopic preschoolers, laying the groundwork for future research.3 'With myopia rising at an alarming rate worldwide, finding effective strategies to slow its progression have never been more urgent,' saidDr. Vlasak. 'With these studies, we continue to provide Eye Care Professionals and parents with confidence through evidence for the benefits of MiYOSMART spectacle lenses, both as a monotherapy and in combination treatment. We are proud to deliver on our mission to protect the long-term vision and quality of life for every child through our evidence-backed myopia management innovations.' For the abstracts presented at ARVO 2025, please visit Product Disclaimer: *MiYOSMART spectacle lenses have not been approved for myopia management in all countries, including the United States, and are not currently available for sale in all countries. View source version on Disclaimer: The above press release comes to you under an arrangement with Business Wire. Business Upturn takes no editorial responsibility for the same. Ahmedabad Plane Crash
Yahoo
3 days ago
- Business
- Yahoo
HOYA Vision Care Unveils Updates from the Association for Research in Vision and Ophthalmology (ARVO) 2025 Annual Meeting
Latest evidence from the world's longest running study on myopia management spectacle lenses reinforced the effectiveness of Defocus Incorporated Multiple Segments (D.I.M.S.) Technology in continuing to significantly reduce myopia progression and axial elongation over 8 years1 Findings from the randomized controlled trial, ASPECT, demonstrated that combining 0.025% atropine drops with DIMS spectacle lenses reduces axial elongation in myopic children2 A first-of-its-kind concept trial showed that D.I.M.S. Technology may offer a protective effect against the development of myopia in pre-myopic preschool children and postpone the onset of myopia3 SALT LAKE CITY, June 12, 2025--(BUSINESS WIRE)--HOYA Vision Care ( today announced new clinical evidence from three key clinical studies highlighting the impact of Defocus Incorporated Multiple Segments (D.I.M.S.) Technology. The results were presented as part of the company's 2025 scientific program, Exploring New Frontiers in Myopia Management with MiYOSMART*, at the Association for Research in Vision and Ophthalmology (ARVO) 2025 Annual Meeting in Salt Lake City, Utah, USA. The latest findings from the world's longest-running clinical study on myopia management spectacle lenses showed that continuous DIMS spectacle lens wear demonstrated significantly reduced myopia progression (-1.00D ± 0.41D, p=0.017) and axial elongation (0.42 ± 0.18 mm, p=0.019) consistently for the full 8 years (n=11) of follow-up.1 This evidence demonstrates that wearing MiYOSMART* spectacle lenses continuously and for the long-term may improve myopia management outcomes. Dr. Natalia Vlasak, Global Head of Medical and Scientific Affairs at HOYA Vision Care said "This landmark study, featuring the longest follow-up to date for myopia management spectacle lenses, reveals that long-term MiYOSMART use continues to significantly slow myopia progression so that children can enjoy their lives to the fullest. These findings emphasize the life-changing value of long-term adherence, providing crucial information and guidance for Eye Care Professionals and parents committed to protecting children's vision health for the future." The first 12-month data readout from the ASPECT randomized controlled trial demonstrated that combining low-dose 0.025% atropine eye drops with DIMS spectacle lenses stopped myopia progression in around 40% of children.2 The mean change in axial length, a key factor in myopia progression, was significantly lower than in the atropine-only group (0.07 ± 0.16 mm vs 0.18 ± 0.16 mm; p<0.001). The researchers also explored vision-related quality of life (VR-QoL), indicating a trend towards improvement in general vision (p=0.049) and competence (p=0.031) in children using low-dose atropine and DIMS spectacle lens combination treatment.4 "Our findings suggest that combining MiYOSMART spectacle lenses with atropine can unlock even greater outcomes for children with myopia progression – marking a positive step towards more personalized, powerful treatment strategies in myopia management that suit the unique needs of each child." said Dr Natalia Vlasak, Global Head of Medical and Scientific Affairs at HOYA Vision Care. A first-of-its-kind pilot study evaluating DIMS spectacle lenses for pre-myopia management in 5- and 6-year-old children indicated that the DIMS technology may offer a protective effect against the development of myopia in this population. Over nine months, the average cycloplegic spherical equivalent refraction (SER) remained stable with a yearly change of +0.06D compared to -0.15D in a control group. While axial length increased slightly (22.48 mm to 22.64 mm, p<0.01), the choroidal thickness remained stable. These promising initial findings suggest MiYOSMART spectacle lenses may help to prevent myopia development and postpone the myopia onset in pre-myopic preschoolers, laying the groundwork for future research.3 "With myopia rising at an alarming rate worldwide, finding effective strategies to slow its progression have never been more urgent," said Dr. Vlasak. "With these studies, we continue to provide Eye Care Professionals and parents with confidence through evidence for the benefits of MiYOSMART spectacle lenses, both as a monotherapy and in combination treatment. We are proud to deliver on our mission to protect the long-term vision and quality of life for every child through our evidence-backed myopia management innovations." For the abstracts presented at ARVO 2025, please visit Product Disclaimer: *MiYOSMART spectacle lenses have not been approved for myopia management in all countries, including the United States, and are not currently available for sale in all countries. View source version on Contacts Pamela Pedrucci PR, Media and External Comms Director HOYA Vision Care Sign in to access your portfolio
Business Wire
3 days ago
- Health
- Business Wire
HOYA Vision Care Unveils Updates from the Association for Research in Vision and Ophthalmology (ARVO) 2025 Annual Meeting
SALT LAKE CITY--(BUSINESS WIRE)--HOYA Vision Care ( today announced new clinical evidence from three key clinical studies highlighting the impact of Defocus Incorporated Multiple Segments (D.I.M.S.) Technology. The results were presented as part of the company's 2025 scientific program, Exploring New Frontiers in Myopia Management with MiYOSMART*, at the Association for Research in Vision and Ophthalmology (ARVO) 2025 Annual Meeting in Salt Lake City, Utah, USA. The latest findings from the world's longest-running clinical study on myopia management spectacle lenses showed that continuous DIMS spectacle lens wear demonstrated significantly reduced myopia progression (-1.00D ± 0.41D, p=0.017) and axial elongation (0.42 ± 0.18 mm, p=0.019) consistently for the full 8 years (n=11) of follow-up. 1 This evidence demonstrates that wearing MiYOSMART* spectacle lenses continuously and for the long-term may improve myopia management outcomes. Dr. Natalia Vlasak, Global Head of Medical and Scientific Affairs at HOYA Vision Care said " This landmark study, featuring the longest follow-up to date for myopia management spectacle lenses, reveals that long-term MiYOSMART use continues to significantly slow myopia progression so that children can enjoy their lives to the fullest. These findings emphasize the life-changing value of long-term adherence, providing crucial information and guidance for Eye Care Professionals and parents committed to protecting children's vision health for the future.' The first 12-month data readout from the ASPECT randomized controlled trial demonstrated that combining low-dose 0.025% atropine eye drops with DIMS spectacle lenses stopped myopia progression in around 40% of children. 2 The mean change in axial length, a key factor in myopia progression, was significantly lower than in the atropine-only group (0.07 ± 0.16 mm vs 0.18 ± 0.16 mm; p<0.001). The researchers also explored vision-related quality of life (VR-QoL), indicating a trend towards improvement in general vision (p=0.049) and competence (p=0.031) in children using low-dose atropine and DIMS spectacle lens combination treatment. 4 "Our findings suggest that combining MiYOSMART spectacle lenses with atropine can unlock even greater outcomes for children with myopia progression – marking a positive step towards more personalized, powerful treatment strategies in myopia management that suit the unique needs of each child." said Dr Natalia Vlasak, Global Head of Medical and Scientific Affairs at HOYA Vision Care. A first-of-its-kind pilot study evaluating DIMS spectacle lenses for pre-myopia management in 5- and 6-year-old children indicated that the DIMS technology may offer a protective effect against the development of myopia in this population. Over nine months, the average cycloplegic spherical equivalent refraction (SER) remained stable with a yearly change of +0.06D compared to -0.15D in a control group. While axial length increased slightly (22.48 mm to 22.64 mm, p<0.01), the choroidal thickness remained stable. These promising initial findings suggest MiYOSMART spectacle lenses may help to prevent myopia development and postpone the myopia onset in pre-myopic preschoolers, laying the groundwork for future research. 3 'With myopia rising at an alarming rate worldwide, finding effective strategies to slow its progression have never been more urgent,' said Dr. Vlasak. 'With these studies, we continue to provide Eye Care Professionals and parents with confidence through evidence for the benefits of MiYOSMART spectacle lenses, both as a monotherapy and in combination treatment. We are proud to deliver on our mission to protect the long-term vision and quality of life for every child through our evidence-backed myopia management innovations.' For the abstracts presented at ARVO 2025, please visit *MiYOSMART spectacle lenses have not been approved for myopia management in all countries, including the United States, and are not currently available for sale in all countries.
Yahoo
07-05-2025
- Health
- Yahoo
Newborn Eye Imaging Systems Market Set to Surpass Valuation of US$ 3.09 Billion By 2033
Retinopathy of prematurity (ROP) is today the single most influential disease variable shaping purchasing behaviour in the new born eye imaging systems market. Current World Health Organization reviews state that ROP is responsible for up to 50,000 cases of childhood blindness each year, with incidence rising in parallel with improved survival of extremely low-birth-weight infants. Screening guidelines in the United States, United Kingdom, Japan, and India uniformly recommend multiple retinal evaluations between postnatal weeks four and twelve. Such dense schedules challenge overstretched ophthalmology teams, thereby accelerating the pivot toward wide-field digital imaging that can be performed by trained NICU nurses under remote ophthalmologist supervision. Hospital administrators additionally note that objective digital documentation creates an auditable clinical record shareable with parents, payers, and public-health databases. Such traceability in the newborn eye imaging systems market streamlines quality-improvement initiatives and supports value-based care incentives now embedded in the United States' Newborn Screening Saves Lives program and Europe's E-Health directives. With global NICU bed capacity forecast to expand by 5% annually through 2028, demand for point-of-care ocular imaging platforms is likely to track in tandem. As a result, the new born eye imaging system market is evolving from a niche adjunct to an indispensable component of neonatal workflow, a transition that continues to influence procurement specifications and vendor roadmaps worldwide. Broader deployment is projected to save caregivers an estimated 12,000 specialist hours per million births annually. Approximately 15 million preterm infants are born each year globally, and close to 12% of them require admission to neonatal intensive care units (NICUs). Within the mechanically ventilated cohort, intermittent hypoxia and systemic instability markedly heighten the risk of ophthalmic complications. Consequently, neonatologists in the newborn eye imaging systems market are under mounting pressure to conduct comprehensive retinal and anterior-segment examinations before discharge. Traditional ophthalmoscopy is operator-dependent and often unfeasible when pupils are poorly dilated. These operational gaps are propelling hospitals to procure high-resolution, non-contact cameras specifically engineered for fragile newborn eyes. Stakeholders recognize that early imaging expedites referral pathways and minimizes medico-legal exposure linked to missed pathology. Chicago, May 07, 2025 (GLOBE NEWSWIRE) -- The global newborn eye imaging systems market was valued at US$ 1.86 billion in 2024 and is expected to US$ 3.09 billion by 2033, growing at a CAGR of 5.81% during the forecast period 2025–2033. Story Continues Latest clinical data presented at the 2024 Association for Research in Vision and Ophthalmology (ARVO) meeting in the newborn eye imaging systems market underscored the technology's impact: centers utilizing 130-degree, high-definition cameras achieved a 28% reduction in missed plus-disease versus indirect ophthalmoscopy alone. At the same meeting, tele-ROP programs from Brazil and South Africa reported that digital imaging cut travel-related screening costs by 40%, reinforcing economic as well as clinical value arguments. Consequently, health ministries are inserting camera-based ROP screening into national essential-equipment lists, a policy shift that substantially enlarges total addressable installations. As vendors integrate artificial-intelligence tools that automatically flag pre-threshold ROP, clinical adoption is expected to intensify, further validating ROP as the dominant driver behind ongoing product innovation and procurement momentum. Expanding Applications Beyond ROP Unlock Broader Clinical And Research Opportunities While ROP continues to headline purchasing dossiers in the newborn eye imaging systems market, clinicians now leverage neonatal ocular imaging for a widening array of pathologies, thereby broadening the commercial horizons of the new born eye imaging system market. Congenital cataract, which affects one to six infants per 10,000 births, represents an urgent indication requiring early photographic documentation to guide surgical timing and postoperative monitoring. Similarly, neonatal herpes simplex keratitis, persistent fetal vasculature, and optic nerve hypoplasia are increasingly identified through handheld spectral-domain OCT and ultra-wide-field cameras. The ability to capture posterior pole and anterior-segment structures in under 30 seconds without pharmacologic dilation enables earlier therapeutic interventions and improves visual prognosis across these conditions. Research applications are expanding just as rapidly in the newborn eye imaging systems market. Investigators at Boston Children's Hospital and the Shanghai Eye & ENT Hospital are incorporating high-resolution neonatal imaging into longitudinal neurodevelopmental studies, correlating retinal microvasculature metrics with cerebral oxygenation profiles. Pharmaceutical companies developing anti-VEGF formulations for paediatric use are also funding imaging-rich registries to satisfy regulatory safety endpoints. Furthermore, public-health agencies in Canada and Australia now include digital retinal photographs within universal newborn metabolic screening pilots to create an integrated ocular-systemic health dataset. These multidisciplinary use cases extend device utilisation beyond the ROP season, driving higher annual throughput and strengthening return-on-investment narratives for hospital CFOs evaluating capital requests. Utilisation has risen from 42% to 50% of NICU days since 2022. Demographic Shifts Highlight High-Risk Patient Cohorts Across Emerging Economies Now Global fertility patterns reveal that the greatest absolute number of annual births—almost 92 million in 2023—occurs in lower-middle-income countries in the newborn eye imaging systems market, where maternal nutrition, antenatal care, and infection-control challenges converge to raise prematurity and low-birth-weight rates. The United Nations Inter-agency Group for Child Mortality Estimation recorded a 35% concentration of preterm deliveries in South Asia alone, producing an expanding cohort of infants susceptible to ROP and other sight-threatening disorders. Simultaneously, urbanisation and improved NICU infrastructure have increased survival of sub-1500-gram neonates, inadvertently exposing more babies to ROP risk windows. These epidemiological realities collectively underpin escalating demand for cost-effective imaging devices tailored to resource-constrained settings. Ageing parents in high-income nations across the global newborn eye imaging systems market constitute an additional demographic driver. Assisted reproductive technologies and advanced maternal age over 35 years are linked with higher rates of multiple gestations and associated prematurity; in the United States, the proportion of births to mothers aged 35-39 climbed to 18% in 2024. Europe mirrors this trajectory, with Italy and Spain reporting record highs of 21% and 19%, respectively. Hospitals serving these populations are consequently integrating routine ocular imaging into NICU and transitional care pathways to pre-empt future litigation and align with family-centered care models. Together, these demographic shifts across disparate economic strata reinforce sustained, multidirectional growth in the new born eye imaging system market. Observers expect these cohorts to dominate procurement through 2030. Pricing Pressures And Reimbursement Trends Influence Hospital Purchase Decisions Globally Capital budgets for neonatal departments remain under intense scrutiny, and price sensitivity continues to shape vendor competition in the newborn eye imaging systems market. Average selling prices for wide-field neonatal fundus cameras range from US$ 55,000 to US$ 85,000 in mature markets, while portable OCT units hover around US$ 40,000. Discounts of up to 20% are increasingly negotiated for multi-unit purchases, a pattern evident in recent NHS Supply Chain tenders. Subscription-based models, whereby hospitals pay a per-scan fee that bundles hardware, cloud storage, and AI analytics, have also gained traction; early adopters in Scandinavia report a 15% reduction in upfront expenditure. Such flexible pricing constructs lower barriers to entry and accelerate fleet upgrades. Reimbursement frameworks are gradually aligning with these commercial shifts in the newborn eye imaging systems market. In the United States, CPT code 92229 for remote retinal imaging became permanent in January 2023, reimbursing approximately US$ 30 per study when interpreted by an ophthalmologist. Germany's Einheitlicher Bewertungsmaßstab added a comparable tele-imaging code in late 2023, and Japan's MHLW followed with a bundled neonatal screening tariff effective April 2024. These policies materially improve ROI calculations, especially when paired with AI-assisted preliminary reads that shorten ophthalmologist review times by nearly 40%. Nonetheless, pay-for-performance initiatives tether reimbursement to documented clinical outcomes, incentivising hospitals to select systems with robust analytics and audit trails, thereby exerting continuous pressure on vendors to demonstrate value beyond acquisition price. Australian payers plan codes 2025. Asia-Pacific And Middle East Offer Lucrative Regional Growth Runways Ahead The Asia-Pacific region exhibits a confluence of favorable parameters in the newborn eye imaging systems market: high birth rates, rapid NICU expansion, proactive government Vision-2025 health agendas, and a flourishing med-tech manufacturing base. India's national ROP taskforce pledged in 2024 to equip every district hospital with digital imaging within three years, a commitment that could catalyze more than 2,000 new installations. China's Healthy Children Initiative sets similar targets, prioritizing AI-enabled screening in county-level maternal hospitals. Private-sector chains such as Apollo Hospitals and Ramsay Sime Darby are likewise standardizing imaging protocols, further amplifying regional demand. This groundswell positions Asia-Pacific as the most dynamic theatre for the new born eye imaging system market over the forecast horizon. Parallel momentum in the newborn eye imaging systems market is visible in select Middle Eastern nations. Saudi Arabia's Vision 2030 e-Health program mandates electronic ocular records for all NICU discharges, while the United Arab Emirates integrates newborn retinal imaging into its mandatory insurance packages. High per-capita health expenditure in Qatar and Kuwait enables rapid adoption of premium devices, including dual-mode OCT-A systems. Additionally, Gulf Cooperation Council buyers favour comprehensive service contracts, pushing lifetime revenue per unit upward. Multinational vendors consequently establish regional training hubs in Riyadh and Dubai, while local distributors negotiate exclusive rights, creating a competitive yet profitable ecosystem. These factors collectively underscore why investors and market entrants increasingly prioritise Asia-Pacific and Middle Eastern geographies within their strategic roadmaps. Approvals average six months. Need Custom Data? Let Us Know: Competitive Landscape Shows Strategic Partnerships, AI Integration, And After-Sales Emphasis The competitive arena in the newborn eye imaging systems market now features a blend of entrenched ophthalmic giants and agile start-ups, each vying to differentiate through ecosystem partnerships. In 2024, Topcon partnered with Google DeepMind to co-develop an on-device ROP triage algorithm, while Canon Medical signed a memorandum with India's Narayana Health to co-create a low-cost camera tailored for tier-2 cities. These alliances accelerate time-to-market and provide built-in distribution channels. Meanwhile, venture funding continues to flow; U.S.-based NeoVision secured US$ 38 million in Series B capital for its handheld OCT-A platform in March 2024, signaling investor confidence despite broader biotech funding headwinds. European players like RetinScan and Forus Health launched multi-country subscription programs, securing framework agreements with four Nordic hospital networks during Q4-2024 to accelerate regionwide deployment. Post-sale service has emerged as a decisive differentiator in the newborn eye imaging systems market. Hospitals increasingly demand 24/7 remote diagnostics, predictive maintenance, and clinician certification program; vendors meeting these needs report contract renewal rates above 90%. Additionally, ESG considerations influence purchasing committees, prompting manufacturers to adopt recyclable packaging and reduced-power standby modes to shrink carbon footprints. Finally, with regulatory bodies tightening cybersecurity requirements, firms emphasizing end-to-end encryption and ISO/IEC 27001 compliance gain a competitive edge. Collectively, these dynamics suggest that future newborn eye imaging systems market winners will be those who combine cutting-edge AI capabilities with robust service infrastructures and sustainability credentials, thereby delivering comprehensive value to the new born eye imaging system market's discerning stakeholder base. Global Newborn Eye Imaging Systems Market Major Players: D-EYE Eye Photo Systems Imagine Eyes MergeHealthcare Natus Medical Servicom Medical Visunex Medical Systems Other Prominent Players Key Segmentation: By Device Type Basic Device Wireless Device By Disease Type ROP Retinal Disease Strabismus Refractive Error Color Blindness Others By End-User Hospitals Ophthalmology Diagnosis Centers Ambulatory Surgical Centers Others By Region North America Europe Asia Pacific Middle East & Africa South America Have Questions? Reach Out Before Buying: About Astute Analytica Astute Analytica is a global market research and advisory firm providing data-driven insights across industries such as technology, healthcare, chemicals, semiconductors, FMCG, and more. We publish multiple reports daily, equipping businesses with the intelligence they need to navigate market trends, emerging opportunities, competitive landscapes, and technological advancements. With a team of experienced business analysts, economists, and industry experts, we deliver accurate, in-depth, and actionable research tailored to meet the strategic needs of our clients. At Astute Analytica, our clients come first, and we are committed to delivering cost-effective, high-value research solutions that drive success in an evolving marketplace. Contact Us: Astute Analytica Phone: +1-888 429 6757 (US Toll Free); +91-0120- 4483891 (Rest of the World) For Sales Enquiries: sales@ Website: Follow us on: LinkedIn | Twitter | YouTube CONTACT: Contact Us: Astute Analytica Phone: +1-888 429 6757 (US Toll Free); +91-0120- 4483891 (Rest of the World) For Sales Enquiries: sales@ Website:
